Total Payments
$13,103
2024 Payments
$3,842
Companies
21
Transactions
145
Medicare Patients
4,815
Medicare Billing
$2.8M
Payment Breakdown by Category
Food & Beverage$6,508 (49.7%)
Other$4,227 (32.3%)
Travel$2,369 (18.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,508 | 125 | 49.7% |
| Travel and Lodging | $2,369 | 5 | 18.1% |
| Current or prospective ownership or investment interest | $2,352 | 5 | 17.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,875 | 2 | 14.3% |
| Unspecified | $0 | 8 | 0.0% |
Payments by Type
General
$13,103
137 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EyePoint Pharmaceuticals US, Inc. | $3,185 | 14 | $0 (2024) |
| Alimera Sciences, Inc. | $3,074 | 25 | $0 (2024) |
| US Retina LLC | $2,352 | 13 | $0 (2024) |
| Spark Therapeutics, Inc. | $1,918 | 4 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $717.33 | 23 | $0 (2024) |
| ABBVIE INC. | $301.35 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $221.37 | 7 | $0 (2020) |
| Mallinckrodt Enterprises LLC | $220.91 | 11 | $0 (2019) |
| Allergan, Inc. | $210.02 | 3 | $0 (2021) |
| Apellis Pharmaceuticals, Inc. | $196.75 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,842 | 36 | EyePoint Pharmaceuticals US, Inc. ($3,080) |
| 2023 | $1,289 | 28 | Alimera Sciences, Inc. ($829.25) |
| 2022 | $2,526 | 25 | Alimera Sciences, Inc. ($1,068) |
| 2021 | $1,585 | 13 | Alimera Sciences, Inc. ($815.82) |
| 2020 | $2,323 | 8 | Spark Therapeutics, Inc. ($1,875) |
| 2019 | $969.40 | 20 | US Retina LLC ($473.75) |
| 2018 | $109.59 | 5 | Carl Zeiss Meditec, Inc. ($49.83) |
| 2017 | $458.98 | 10 | Allergan Inc. ($124.24) |
All Payment Transactions
145 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $31.15 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/14/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Ophthalmology | ||||||
| 11/22/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $30.49 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $1,075.66 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $345.75 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $218.68 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | Cash or cash equivalent | $119.05 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | Cash or cash equivalent | $90.00 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $27.81 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $26.29 | General |
| Category: EYE CARE | ||||||
| 11/04/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/28/2024 | EyePoint Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $27.45 | General |
| 10/25/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $27.99 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 10/23/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: EYE CARE | ||||||
| 10/10/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $29.70 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 09/19/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/30/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: Ophthalmology | ||||||
| 07/26/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: Ophthalmology | ||||||
| 07/22/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/20/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $34.35 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/12/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $136.96 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 05/29/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,398 | 4,079 | $2.0M | $880,959 |
| 2022 | 13 | 1,175 | 2,794 | $1.1M | $561,752 |
| 2021 | 14 | 1,175 | 3,128 | $1.2M | $660,215 |
| 2020 | 11 | 1,067 | 3,377 | $1.4M | $723,850 |
Total Patients
4,815
Total Services
13,378
Medicare Billing
$2.8M
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 99 | 958 | $1.2M | $660,357 | 55.1% |
| 67028 | Injection of drug into eye | Office | 2023 | 188 | 725 | $337,950 | $70,479 | 20.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 16 | 265 | $129,200 | $48,274 | 37.4% |
| 92134 | Imaging of retina | Office | 2023 | 372 | 1,025 | $85,350 | $28,381 | 33.3% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 210 | 280 | $50,690 | $21,917 | 43.2% |
| J3590 | Unclassified biologics | Office | 2023 | 86 | 312 | $62,400 | $19,727 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 132 | $28,270 | $11,536 | 40.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 51 | 58 | $11,780 | $5,717 | 48.5% |
| 92250 | Photography of the retina | Office | 2023 | 176 | 209 | $30,300 | $5,147 | 17.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $7,210 | $3,484 | 48.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 35 | $4,325 | $2,317 | 53.6% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 21 | 21 | $4,545 | $2,123 | 46.7% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 11 | 15 | $1,900 | $991.19 | 52.2% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 14 | 15 | $1,520 | $508.22 | 33.4% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 71 | 602 | $752,500 | $432,195 | 57.4% |
| 67028 | Injection of drug into eye | Office | 2022 | 133 | 456 | $113,810 | $42,569 | 37.4% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 204 | 302 | $54,360 | $24,363 | 44.8% |
| 92134 | Imaging of retina | Office | 2022 | 317 | 788 | $59,100 | $21,838 | 37.0% |
| J3590 | Unclassified biologics | Office | 2022 | 63 | 203 | $45,700 | $16,549 | 36.2% |
| 92250 | Photography of the retina | Office | 2022 | 188 | 232 | $34,800 | $5,952 | 17.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 44 | 44 | $10,780 | $5,339 | 49.5% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 47 | 52 | $9,880 | $4,586 | 46.4% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 38 | 38 | $8,170 | $4,190 | 51.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 27 | 30 | $4,500 | $2,084 | 46.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 13 | $1,300 | $790.10 | 60.8% |
About Dr. Liliya Sutherland, D.O
Dr. Liliya Sutherland, D.O is a Ophthalmology healthcare provider based in Grand Rapids, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1942463252.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Liliya Sutherland, D.O has received a total of $13,103 in payments from pharmaceutical and medical device companies, with $3,842 received in 2024. These payments were reported across 145 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($6,508).
As a Medicare-enrolled provider, Sutherland has provided services to 4,815 Medicare beneficiaries, totaling 13,378 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Grand Rapids, MI
- Active Since 07/07/2008
- Last Updated 01/26/2021
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1942463252
Products in Payments
- EYP-1901 (Drug) $3,053
- ILUVIEN (Drug) $2,693
- LUXTURNA (Biological) $1,918
- EYLEA (Biological) $513.18
- OZURDEX (Drug) $452.05
- YUTIQ (Drug) $398.54
- ACTHAR (Biological) $243.02
- Syfovre (Drug) $164.23
- EYLEA AFLIBERCEPT INJECTION (Biological) $110.53
- XIPERE (Drug) $105.57
- EYLEA HD (Biological) $93.62
- Iluvien (Drug) $86.61
- BEOVU (Drug) $70.94
- VABYSMO (Drug) $69.72
- Non-Covered Product (Drug) $63.64
- OPMI Lumera (Device) $49.83
- Lucentis (Biological) $43.26
- DURYSTA (Drug) $34.45
- PURIFIED CORTROPHIN GEL (Drug) $31.15
- Humira (Biological) $24.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Grand Rapids
Dr. Thomas Aaberg, Md, MD
Ophthalmology — Payments: $329,714
Ophthalmology $329,714
Scott Westhouse, D.o, D.O
Ophthalmology — Payments: $96,762
Ophthalmology $96,762
Dr. Edward Korot, M.d, M.D
Ophthalmology — Payments: $43,512
Ophthalmology $43,512
Roman Krivochenitser, M.d, M.D
Ophthalmology — Payments: $21,287
Ophthalmology $21,287
Dr. Joseph Boss, M.d, M.D
Ophthalmology — Payments: $21,268
Ophthalmology $21,268
Dr. Marcus Muallem, Md, MD
Ophthalmology — Payments: $14,992
Ophthalmology $14,992